RESUMEN
Hancornia speciosa is a medicinal plant with proven antihypertensive activity. The cyclitol l-(+)-bornesitol is the main constituent of its leaves and is a potent inhibitor of the angiotensin-converting enzyme. We herein investigated the pharmacokinetic properties of bornesitol administered orally to Wistar rats, as well as bornesitol permeation in Caco-2 cells. Bornesitol was isolated and purified from an ethanol extract of H. speciosa leaves. An ultra-high performance liquid chromatography coupled with electrospray ionization mass spectrometry (UPLC-ESI-MS/MS) method was developed and validated to quantify bornesitol in rat plasma based on Multiple Reaction Monitoring, using pentaerythritol as an internal standard. Pharmacokinetics was evaluated by the administration of single doses via intravenous in bolus (3â¯mg/kg) and gavage (3, 15 and 25â¯mg/kg). Bornesitol permeation was assayed in a transwell Caco-2 cells model, tested alone, or combined with rutin, or as a constituent of H. speciosa extract, using a developed and validated UPLC-ESI-MS/MS method. All assayed validation parameters (selectivity, residual effect, matrix effect, linearity, precision, accuracy and stability of analyte in plasma and solution) for the bioanalytical method met the acceptance criteria established by regulatory guidelines. Bornestiol reached peak plasma concentration within approximately 60â¯min after oral administration with a half-life ranging from 72.15â¯min to 123.69â¯min. The peak concentration and area under the concentration-time curve of bornesitol did not rise proportionally with the increasing doses, suggesting a non-linear pharmacokinetics in rats and the oral bioavailability ranged from 28.5%-59.3%. Bornesitol showed low permeability in Caco-2 cells, but the permeability apparently increased when it was administered either combined with rutin or as a constituent of H. speciosa extract. In conclusion, bornesitol was rapidly absorbed after a single oral administration to rats and followed a non-linear pharmacokinetics. The obtained data will be useful to guide further pre-clinical development of bornesitol-containing herbal preparations of H. speciosa as an antihypertensive agent.
Asunto(s)
Antihipertensivos/farmacocinética , Apocynaceae , Cromatografía Líquida de Alta Presión , Ciclitoles/farmacocinética , Extractos Vegetales/farmacocinética , Espectrometría de Masa por Ionización de Electrospray , Espectrometría de Masas en Tándem , Administración Oral , Animales , Antihipertensivos/administración & dosificación , Antihipertensivos/sangre , Antihipertensivos/aislamiento & purificación , Apocynaceae/química , Disponibilidad Biológica , Células CACO-2 , Ciclitoles/administración & dosificación , Ciclitoles/sangre , Ciclitoles/aislamiento & purificación , Humanos , Inyecciones Intravenosas , Absorción Intestinal , Mucosa Intestinal/metabolismo , Masculino , Modelos Biológicos , Dinámicas no Lineales , Permeabilidad , Extractos Vegetales/administración & dosificación , Extractos Vegetales/sangre , Extractos Vegetales/aislamiento & purificación , Ratas WistarRESUMEN
The leaves of Hancornia speciosa Gomes (Apocynaceae), a medicinal species found in the Brazilian cerrado biome, are traditionally used to treat wounds and inflammatory disorders. The goal of the present study was to investigate the in vitro wound healing properties of ethanolic extract of H. speciosa leaves and its isolated compounds, using the scratch assay, and to evaluate their effects on the release of the pro-inflammatory cytokine tumor necrosis factor (TNF-α) by lipopolysaccharide (LPS)-stimulated human acute monocytic (THP-1) cells. H. speciosa ethanolic extract significantly increased (42.8% ± 5.4 at 25 µg/mL) cell migration and proliferation of fibroblasts compared with control cells, as well as the isolated compounds bornesitol (80.8% ± 5.1) and quinic acid (69.1% ± 6.2), both assayed at 50 µM. TNF-α release by LPS-stimulated THP-1 cells was significantly reduced by the ethanolic extract (62.9% ± 8.2, i.e. 1791.1 ± 394.7 pg/mL) at 10 µg/mL, bornesitol (48.9% ± 0.9, i.e. 2461.6 ± 43.1 pg/mL) at 50 µM, and quinic acid (90.2% ± 3.4, i.e. 473.5 ± 164.4 pg/mL) and rutin (82.4% ± 5.6, i.e. 847.0 ± 271.8 pg/mL) at 10 µM. These results provided evidences to support the traditional use of H. speciosa leaves to treat wounds and inflammatory disorders.
Asunto(s)
Apocynaceae/química , Fibroblastos/efectos de los fármacos , Extractos Vegetales/farmacología , Cicatrización de Heridas/efectos de los fármacos , Brasil , Línea Celular , Ciclitoles/aislamiento & purificación , Ciclitoles/farmacología , Humanos , Lipopolisacáridos , Hojas de la Planta/química , Ácido Quínico/aislamiento & purificación , Ácido Quínico/farmacología , Rutina/aislamiento & purificación , Rutina/farmacología , Factor de Necrosis Tumoral alfa/metabolismoRESUMEN
ETHNOPHARMACOLOGICAL RELEVANCE: The leaves of Hancornia speciosa Gomes are traditionally used to treat diabetes in Brazil. The aim of the study is to evaluate the potential anti-diabetic effect of Hancornia speciosa extract and derived fractions. MATERIALS AND METHODS: The ethanolic extract from Hancornia speciosa leaves and chromatographic fractions thereof were evaluated on α-glucosidase assay, on hyperglycemic effect and glucose uptake. The chemical composition of the extract and its most active fraction was investigated by ESI-LC-MS. RESULTS: The ethanolic extract and derived fractions inhibited α-glucosidase in vitro. However, only the crude extract and the dichloromethane fraction inhibited the hyperglycemic effect induced by starch or glucose. Both the extract and dichloromethane fraction were also able to increase glucose uptake in adipocytes. Bornesitol, quinic acid, and chorogenic acid were identified in the extract, along with flavonoid glycosides, whereas the dichloromethane fraction is majorly composed by esters of lupeol and/or α/ß-amirin. CONCLUSIONS: Hancornia speciosa has a potential anti-diabetic effect through a mechanism dependent on inhibition of α-glucosidase and increase on glucose uptake. These results give support to the use on traditional medicine of this medicinal plant.
Asunto(s)
Apocynaceae , Inhibidores de Glicósido Hidrolasas/farmacología , Extractos Vegetales/farmacología , Adipocitos/efectos de los fármacos , Adipocitos/metabolismo , Animales , Glucemia/análisis , Brasil , Ácido Clorogénico/aislamiento & purificación , Ciclitoles/aislamiento & purificación , Glucosa/metabolismo , Masculino , Medicina Tradicional , Ratones , Hojas de la Planta , Ácido Quínico/aislamiento & purificaciónRESUMEN
Hancornia speciosa Gomes (Apocynaceae) is a Brazilian plant traditionally employed to treat inflammatory conditions, among other uses. The chemopreventive effect of an ethanol extract from H. speciosa leaves (EHS) was evaluated in a battery of in vitro tests [inhibition of aromatase, NF-kappaB and ornithine decarboxylase (ODC), antioxidant response elements (ARE) induction and cell proliferation assays]. Bioassay-directed fractionation of EHS following by inhibition of 12-O-tetradecanoyl-13-acetate (TPA)-mediated NF-kB activation led to the isolation of the cyclitols quinic acid (1) (85.0+/-12.3 microM) and l-(+)-bornesitol (2) (IC(50)=27.5+/-3.8 microM), along with rutin (26.8+/-6.3 microM). Based on these lead compounds, the cyclitols per-O-acetyl-1l-(+)-bornesitol (3) (IC(50)=38.4+/-6.2 microM), myo-inositol (4) (>180.2 microM), scyllo-inositol (5) (83.0+/-13.7 microM) and beta-d-galactoside-myo-inositol (6) (52.4+/-8.4 microM) were evaluated in the assay, but found to be somewhat less active than 1 and 2. None of the compounds was active in the ARE, aromatase or ODC assays and did not inhibit proliferation of MCF-7, LNCaP, HepG2 or LU-1 cell lines at a final concentration of 20 microg/ml (equivalent to 104.07-32.76 microM).This work identifies l-(+)-bornesitol, quinic acid and rutin as NF-kappaB inhibitors of H. speciosa and suggests cyclitols, in addition to myo-inositol, are potentially useful as chemopreventive agents.